Historical Stock Chart
6 Months : From Jun 2019 to Dec 2019
By Colin Kellaher
Merck & Co. (MRK) on Tuesday said the U.S. Food and Drug Administration accepted for review applications to include an every-six-weeks dosing schedule for its cancer drug Keytruda in six indications.
The Kenilworth, N.J., drug maker said it filed the six supplemental biologics license applications to update the dosing frequency for Keytruda in melanoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, gastric cancer, hepatocellular carcinoma and Merkel cell carcinoma.
Merck said the agency has set a target action date of Feb. 18, 2020.
Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is currently approved for dosing every three weeks.
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
July 09, 2019 07:12 ET (11:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.